Health Economic Assessment of Lower Extremity Diabetic (HEALED) Ulcers With PriMatrix

NCT ID: NCT01729286

Last Updated: 2016-10-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to compare the effectiveness of PriMatrix Moist Wound Therapy (MWT) with Standard of Care MWT for the treatment of chronic diabetic foot ulcers in subjects with diabetes mellitus and without significantly compromised arterial circulation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be a multi-center, prospective, randomized single-blinded study evaluating the efficacy of PriMatrix MWT versus Standard of Care MWT in achieving complete wound closure of chronic diabetic foot ulcers by 12 weeks (84 days). To measure wound recidivism and changes in functional quality of life, each subject will complete the Cardiff Wound Impact Schedule and the SF-36v2™ at three time points during the study i) at initial screening, ii) at completion of treatment phase, and iii)at 24 weeks (post-randomization). Additionally, the data obtained from the SF-36v2™ will be used in an economic evaluation of the treatment arms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Foot Ulcer, Diabetic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PriMatrix Moist Wound Therapy

sharp debridement, Primatrix, a dressing regimen that maintains a moist wound healing environment, and offloading

Group Type ACTIVE_COMPARATOR

PriMatrix Moist Wound Therapy

Intervention Type DEVICE

sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading

Standard of Care Moist Wound Therapy

Intervention Type OTHER

sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading

Standard of Care Moist Wound Therapy

sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading

Group Type OTHER

Standard of Care Moist Wound Therapy

Intervention Type OTHER

sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PriMatrix Moist Wound Therapy

sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading

Intervention Type DEVICE

Standard of Care Moist Wound Therapy

sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PriMatrix Dermal Repair Scaffold

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type I or Type II diabetes
* A diabetic foot ulcer located on the foot or ankle at least one square centimeter

Exclusion Criteria

* Suspected or confirmed signs/symptoms of wound infection
* Hypersensitivity to bovine collagen
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Integra LifeSciences Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John Starinski, DPM

Role: STUDY_CHAIR

TEI

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Southern California

Los Angeles, California, United States

Site Status

Foot and Ankle Clinic

Los Angeles, California, United States

Site Status

Advanced Research Institute of Miami

Miami, Florida, United States

Site Status

Advanced Foot & Ankle Specialists

Tampa, Florida, United States

Site Status

Joseph M. Still Research Foundation

Augusta, Georgia, United States

Site Status

American Health Network

Carmel, Indiana, United States

Site Status

Foot & Andle Center of Mooresville

Mooresville, Indiana, United States

Site Status

Imperial Health

Lake Charles, Louisiana, United States

Site Status

Kansas City Vascular

North Kansas City, Missouri, United States

Site Status

St. Anthony's Medical Center

St Louis, Missouri, United States

Site Status

North Shore Long Island Jewish Comprehensive Wound Healing Center

Lake Success, New York, United States

Site Status

Wake Forest University

Winston-Salem, North Carolina, United States

Site Status

Fairfield Medical Center

Lancaster, Ohio, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

University of Tennessee

Memphis, Tennessee, United States

Site Status

Centro Podiatrico del Norte

Arecibo, , Puerto Rico

Site Status

Renier Gonzalez-Cruz

Juana Díaz, , Puerto Rico

Site Status

VA Carribean Healthcare System

San Juan, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Puerto Rico

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TEI-007

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment of PRP on Diabetes Wound
NCT02088268 COMPLETED NA